Close Menu

NEW YORK – Investment bank SVB Leerink said on Thursday that it is initiating coverage of Natera with an "Outperform" rating and a price target of $75 per share.

"[Natera] to us is a leading reproductive testing company with a rapidly growing position in oncology that is addressing a $21 [billion total addressable market] in three core diagnostics end markets," Leerink analyst Puneet Souda wrote in a note to investors.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.